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Skin disease and its therapy affect health-related quali-
ty of life (HRQoL). The aim of this study was to measure 
the burden caused by dermatological therapy in 3,846 
patients from 13 European countries. Adult outpa-
tients completed questionnaires, including the Derma-
tology Life Quality Index (DLQI), which has a therapy 
impact question. Therapy issues were reported by a 
majority of patients with atopic dermatitis (63.4%), 
psoriasis (60.7%), prurigo (54.4%), hidradenitis sup-
purativa (54.3%) and blistering conditions (53%). The 
largest reduction in HRQoL attributable to therapy, as 
a percentage of total DLQI, adjusted for confounders, 
was seen in blistering conditions (10.7%), allergic/
drug reactions (10.2%), psoriasis (9.9%), vasculi-
tis/immunological ulcers (8.8%), atopic dermatitis 
(8.7%), and venous leg ulcers (8.5%). In skin cancer, 
although it had less impact on HRQoL, the reduction due 
to therapy was 6.8%. Treatment for skin disease con-
tributes considerably to reducing HRQoL: the burden 
of dermatological treatment should be considered 
when planning therapy and designing new dermatolo-
gical therapies.
Key words: quality of life; HRQoL; DLQI; dermatological 
therapy; burden of skin disease; therapy burden.
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Topical and other dermatological therapies can add to the burden of skin disease, as they may be time-
consuming, messy, intervene with clothing choice, and 
impact on health-related quality of life (HRQoL) in ways 
that are unique to the skin (1, 2). This contrasts with the 
relatively low burden of oral therapy in other diseases 
(3) where, for most, oral medication becomes routine. 
However, even systemic dermatological medications, 
such as cytotoxic drugs, corticosteroids, retinoids, in-
travenous or injected biologics, may have an associated 
burden. Topical and injection routes of drug administra-
tion have the lowest levels of convenience and global 
satisfaction (4).
Impairment of HRQoL due to dermatological therapy 
is little explored, even though the burden caused by skin 
disease treatment is very important, both to patients and 
because it contributes to poor adherence (5).
Most generic measures of HRQoL were developed 
with out including skin diseases. It is therefore unsur-
prising that they miss the burden experienced by derma-
tological patients. In measures designed for use across 
skin diseases, only the Dermatology Life Quality Index 
(DLQI) includes a question concerning the impact of 
treatment on everyday life (6).
The aim of this study was to measure how therapy for 
skin disease contributes to reducing HRQoL in outpa-
tients across Europe.
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SIGNIFICANCE
Treatments for skin diseases differ from those used for 
other diseases. They may be messy, time-consuming, 
affect clothing or be painful. Some diseases are burden-
some (psoriasis, eczemas, itching) and their therapy 
causes extra impairment, which should be appreciated. 
Others showed little impact from therapy, although the 
diseases themselves were serious (hidradenittis suppu-
rativa, psycho dermatological conditions, acne). Adequate 
therapy should be sought to alleviate symptoms without 
adding further impairment. Lastly, some skin diseases 
stood out as more burdened by therapy than by the di-
sease itself (cancer, allergies, scars). For these patients, 
choice of therapy is most important for providing optimal 
help.
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METHODS
Data were obtained from a cross-sectional multicentre study on 
patients recruited from 15 dermatological outpatient clinics in 13 
European countries: details have been previously reported (7). 
The study was approved by the Regional Committee for Medical 
Research Ethics in Norway. Separate ethical approvals were ob-
tained where necessary. The study was conducted in accordance 
with the Declaration of Helsinki.
Consecutive patients, age over 18 years, understanding the local 
language and not having severe mental disease were invited to 
participate on random days, giving written consent. Participants 
completed questionnaires on sociodemographics (sex, age, ethni-
city, education, marital and socioeconomic status), the DLQI and 
other questionnaires (7–11).
Patients were examined by the dermatologist, who recorded co-
morbidities: diabetes mellitus, cardiovascular, chronic respiratory, 
rheumatological or other disease. Workers from each hospital’s 
service division were invited to participate as controls.
The DLQI, a 10-item questionnaire, was used to assess im-
pairment in HRQoL. Question 10, which concerns the impact 
of therapy, was used to assess how treatment impaired HRQoL: 
“How much of a problem has the treatment for your skin been, for 
example by making your home messy, or by taking up time?” with 
possible answers “very much” (scored 3), “a lot” (2), “a little” (1) 
or “not at all/not relevant” (0).
The DLQI was not designed for use by healthy individuals. 
Patients with naevi (n = 192) served as “healthy” controls, since 
there were no significant differences between the patients with 
naevi and healthy controls (7, 8).
Statistical analysis
Data from all centres were merged. Diagnoses were organized 
into 35 disease groups (8, 12).
SPSS 24 software was used for statistical analysis. Frequencies 
and means for patient and control characteristics were calculated.
The answers to DLQI question 10 were dichotomized into 
“no impairment” (0) or “impaired” (1, 2 or 3) when calculating 
frequencies of positive answers.
For each diagnosis the mean scores for question 10 and total 
DLQI were calculated. Their relationship was calculated as
(mean score Question 10 ×100mean total DLQI score ), denoted as Q10%.
Comparisons between patients with naevi and healthy controls 
were performed with the t-test for continuous variables (age) and 
the χ2 test for categorical variables (sex, marital status, socioecono-
mic status, comorbidities, economic difficulties, stress, depression 
and anxiety (7)) and linear (EQ-VAS) and logistic regressions 
(EQ5D) for comparing HRQoL outcomes (8).
Linear regression was performed to analyse Q10% for each 
diagnosis, adjusting for age, sex, socioeconomic status and co-
morbidity with “naevi” as controls.
A search for publications on therapy issues in dermatology using 
DLQI or other instruments was performed using MEDLINE, EM-
BASE and Cochrane Library following standard search strategies. 
Search terms and medical descriptors (MeSH) included skin di-
sease, dermatosis, dermatoses, quality of life, DLQI, skin therapy, 
topical therapy, photodynamic therapy, cryotherapy, cryosurgery, 
cryoablation, laser, phototherapy, photochemotherapy, ultraviolet 
B (UVB), UVA, UVA1, psoralen plus UVA (PUVA), retinoid 
plus PUVA (RePUVA), topical drug administration, parenteral 
administration, biological therapy, tumour necrosis factor (TNF)-α 
inhibitors, infusion therapy, skin cancer therapy, and surgical 
dermatological therapy.
RESULTS
Participants
There were 4,010 participants and 1,359 healthy controls. 
Comparative details have been published previously 
(7–11) and are given briefly in Table SI1.
Dermatology Life Quality Index data
There were 3,846 (96%) valid answers to DLQI, 5.2% 
of which had a DLQI > 20 (extremely large effect on 
HRQoL). One-fifth (20.3%) experienced at least a very 
large effect (DLQI > 11) and 44.9% had a DLQI > 6, mea-
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2918
Table I. Frequencies of Dermatology Life Quality Index (DLQI) scores (n=3,846)
DLQI score band descriptors (ref. 6, 13) Valid % Number
Cumulative %
DLQI score
Extremely large (21–30)   5.2 200   5.2% >20
Very large (11–20) 20.3 782 25.5% >11
Moderate (6–10) 19.4 745 44.9% > 6
Small (2–5) 26.6 1,023 71.5% > 2
No (0–1) 28.5 1,096
Total 3,846
Mean DLQI (SD). n=Valid number of patients
Sex Male: 6.4 (6.7) n = 1,686 Female: 7 (6.8) n = 2,168
Age groups 18–35 years:
7.34 (6.8) n = 1,247
36–65 years:
6.94 (7) n = 1,880
> 66 years:
5.06 (5.9) n = 652
Socioeconomic status Low:
8.22 (7.2) n = 720
Middle:
6.44 (6.6) n = 2,844
High:
5.88 (5.9) n = 327
Comorbidity None: 6.74 (6.7) N=2,573 Any: 6.89 (6.9) N=1,033
BE DK FR GER HU ITa NL NOb PL RUS ES TR UK
3.38 (3.9) 5.79 (6.7) 4.58 (5.3) 7.14 (7.4) 7.26 (7.3) 8.01 (6.7) 5.09 (5.7) 6.99 (6.7) 10.89 (7.8) 10.38 (7.0) 2.26 (3.6) 7.35 (5.6) 5.23 (6.8)
n = 250 n = 265 n = 126 n = 290 n = 261 n = 527 n = 235 n = 534 n = 275 n = 273 n = 274 n = 270 n = 213
aPadua and Rome. bOslo and Stavanger.
BE: Belgium; DK: Denmark; FR: France; GER: Germany; HU: Hungary; IT: Italy; NL: The Netherlands; NO: Norway; PL: Poland; RUS: Russia; ES: Spain; TR: Turkey; 
UK: United Kingdom.
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ning at least a moderate effect on HRQoL (13) caused 
by their skin disease (Table I).
The total patient population (n = 3,846) had a mean ± 
standard deviation (SD) DLQI score of 6.7 ± 6.8, meaning 
moderately impaired HRQoL. Except for naevi, no skin 
disease had a mean score < 2, so all had at least a small 
effect on patients’ HRQoL. Twenty-seven of the 35 (77%) 
skin conditions had mean DLQI scores > 5, indicating 
at least a moderate effect on a patient’s life (Table SII1).
Higher DLQI values, indicating higher impairment, 
were seen in females, younger age groups, patients 
with comorbidities and those with lower socioeconomic 
status.
Therapy impact data (DLQI question 10)
Question 10 in the DLQI addresses therapy-related is-
sues. The numbers of patients answering with “a little”, 
“a lot” or “very much”, i.e. other than “no impact/not 
relevant”, are given in Fig. 1. More than half of the 
patients with atopic dermatitis (AD) (63.4%), prurigo 
(60.7%), psoriasis (54.4%), hidradenitis suppurativa 
(HS) (54.3%) or blistering disorders (53%) answered 
positively. Fifteen of 32 skin conditions had > 33.3% 
patients scoring positively.
The mean scores with SD for question 10 and Q10% 
for each diagnosis are presented in Table II. There are no 
existing cut-off values for interpreting results from single 
questions of the DLQI, and isolated values may not give 
a clear perspective as to how large the impact is. Q10% 
is not a standardized method for interpreting DLQI data, 
but does provide perspective on how therapy issues relate 
to the total HRQoL impairment. Table II lists the diseases 
in descending values according to Q10%, adjusted for 
age, sex, socioeconomic status and comorbidity. The po-
sitive standardized β coefficients for all diseases denote 
influence of therapy on HRQoL even when adjusted. 
For many diseases the β coefficient was relatively high, 
indicating robustness of the presented results.
When assessing Q10%, males and older patients sho-
wed more impairment, the reverse of what was seen for 
total mean DLQI. The impairment was highest in patients 
with comorbidities or those of low socioeconomic status.
When considering the impact of therapy on HRQoL, 
highest mean scores and most positive answers to ques-
tion 10 were seen in diseases that commonly affect large 
areas of the skin (e.g. AD, psoriasis, allergic/drug/pho-
totoxic conditions, prurigo, papulosquamous diseases, 
eczemas, connective tissue disease and vitiligo), as well 
as diseases accompanied by blisters/erosions, ulcera-
tion or crusting (blistering diseases, venous leg ulcer, 
vasculitis, immunological ulcers and oral diseases) and 
pruritic dermatoses (prurigo, urticaria and pruritus) 
(Table II, Fig. 1).
Q10% reveals which diagnostic groups are most affec-
ted by therapy relative to their total HRQoL impairment. 
Blistering conditions showed the highest value (10.7), 
followed by allergic, drug, phototoxic/-allergic reactions 
(10.2) and psoriasis (9.9), a ranking that differs from total 
mean DLQI values (Table SII1). This gives insight into 
the true extra burden of therapy for different diseases.
HS, prurigo, pruritus and urticaria show the highest 
impairment when mean DLQI scores are evaluated, but 
drop in ranking when therapy is assessed. Likewise, 
acne, rosacea and psychodermatological conditions, 
scoring among the average impaired as measured by 
mean DLQI scores, were some of the least affected 
by therapy. Conversely, blistering conditions, non-
melanoma skin cancer (NMSC), actinic keratoses (AK), 
allergic/drug reactions, vasculitis and venous leg ulcers 
rank higher when evaluated according to therapy-related 
impairment.
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Fig. 1. The percentage of positive answers to having therapy issues (Question 10 of the DLQI) for each diagnosis. Diagnoses represented 
by fewer than 20 valid answers (hyperhidrosis (12), nail diseases (17) and granuloma annulare (13) excluded). NMSC: non-melanoma skin cancer.
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DISCUSSION
Using a dermatology-specific measure this study iden-
tified the extent of the reduced HRQoL associated with 
therapy. For several diseases, patients experience a high 
burden associated with therapy (blistering conditions, 
allergic/drug reactions, psoriasis, vasculitis, vitiligo 
and venous leg ulcers). Ranking the diseases according 
to what percentage of the burden is caused by therapy 
gives new insight into this specific impairment for the 
separate diagnoses.
Most skin diseases are treated with topical therapy. 
However, dermatological treatments include oral therapy, 
phototherapy, photodynamic therapy, lasers, cryotherapy, 
intralesional and surgical procedures and parenteral ad-
ministrations, which may be painful, time-consuming 
or cause infusion reactions. The use of these specific 
dermatological medications and therapeutic approaches 
presents issues and challenges unique to skin disease.
Generic HRQoL measures have been developed 
without specific reference to the impact of therapy for 
skin disease (Table III). Assessment may therefore be 
inaccurate if this burden experienced by dermatological 
patients is missed. There are no questions related to the 
impact of therapy in the most commonly used generic 
measures. However, the generic measures Treatment Sa-
tisfaction with Medicines Questionnaire (SATMED-Q) 
(3) and Treatment Satisfaction Questionnaire for Medi-
cation (TSQM) (4) are designed to address issues with 
medication, but are little used in dermatology. The DLQI 
is the only non-disease-specific dermatological measure 
Table II. Effect of treatment on Dermatology Life Quality Index (DLQI). Ranking according to the percentage of Question 10 of the DLQI (therapy 
issues) to the mean total DLQI (Q10%) for diagnoses with at least 20 valid answers (hyperhidrosis (12), nail diseases (17) and granuloma annulare (13) 
excluded). Linear regression (standardized β) with “naevi” as a “healthy” control group, adjusting for age, sex, socioeconomic status and comorbidity 
(diabetes mellitus, cardiological, respiratory, rheumatological or other disease)
Diagnosis Q10%a
Standardized 
β
Question 10 
Mean ± SD
DLQI
Mean ± SD Valid n/Valid n βb
All patientsc   7.73 0.06 0.52 ± 0.8 6.73 ± 6.8 3,846/3,553
1 Blistering conditions 10.71 0.47 0.92 ± 1.0 8.59 ± 7.4   66/49
2 Allergic, drug, phototoxic/-allergic reactions 10.21 0.39 0.54 ± 0.8 5.29 ± 4.3   24/21
3 Psoriasis 9.85 0.19 0.90 ± 1.0 9.14 ± 7.6 660/615
4 Vasculitis and immunological ulcersd 8.78 0.28 0.62 ± 0.9 7.06 ± 6.1   67/60
5 Atopic dermatitis 8.67 0.33 1.0 ± 0.9 11.53 ± 7.2 172/150
6 Vitiligo 8.62 0.36 0.33 ± 0.6 3.83 ± 3.7   24
7 Venous leg ulcers 8.47 0.27 0.80 ± 1.0 9.45 ± 7.3 113/87
8 Other hair disorderse 8.38 0.27 0.42 ± 0.8 5.01 ± 5.4   82/76
9 Prurigo 8.13 0.33 0.93 ± 0.9 11.44 ± 8.2   27/24
10 Scars, fibrosis of the skin, morphea 8.11 0.24 0.43 ± 0.9 5.3 ± 4.8   27
11 Papulosquamous skin diseasesf 7.69 0.21 0.49 ± 0.8 6.37 ± 6.4 113/103
12 Connective tissue disease 7.43 0.20 0.58 ± 0.9 7.81 ± 7.0   91/74
13 Oral conditionsg 7.39 0.24 0.50 ± 0.8 6.77 ± 6.6   26
14 Eczema 7.36 0.21 0.62 ± 0.9 8.42 ± 7.2 234
15 Urticaria 7.09 0.35 0.68 ± 0.9 9.59 ± 6.7   69/60
16 Hand eczema 7.05 0.18 0.60 ± 0.9 8.51 ± 7.2 156/146
17 Alopecia areata 6.99 0.18 0.39 ± 0.8 5.58 ± 6.8   31/30
18 Pruritus 6.84 0.24 0.75 ± 1.0 10.97 ± 7.1   60/58
19 Non-melanoma skin cancer and actinic keratosis 6.75 0.11 0.16 ± 0.5 2.37 ± 5.0 401/372
20 Genital (non-venereal)h 6.36 0.22 0.56 ± 0.8 8.81 ± 6.4   32/30
21 Otheri 6.15 0.20 0.39 ± 0.7 6.34 ± 6.6   96/67
22 Hidradenitis suppurativa 6.14 0.24 0.78 ± 0.8 12.7 ± 7.6   46/44
23 Infections of the skin 6.09 0.21 0.38 ± 0.8 6.24 ± 5.8 253/244
24 Benign skin tumours 5.51 0.09 0.15 ± 0.5 2.72 ± 3.7 159/154
25 Lichen planus 5.42 0.07 0.33 ± 0.7 6.09 ± 5.4   46/41
26 Seborrhoeic dermatitis 5.41 0.23 0.34 ± 0.6 6.28 ± 4.4   75/74
27 Psychodermatological conditions 5.41 0.14 0.46 ± 0.8 8.5 ± 7.1   34
28 Acne 4.99 0.16 0.31 ± 0.6 6.21 ± 5.2 234/228
29 Rosacea 4.66 0.09 0.25 ± 0.6 5.37 ± 5.3   75/68
30 Naevi 4.61 – 0.07 ± 0.3 1.52 ± 2.9 186
31 Malignant melanoma 4.41 0.03 0.12 ± 0.4 2.72 ± 4.4   86/75
32 Melasma, pigment disorders 2.01 0.16 0.10 ± 0.3 4.97 ± 4.7   32/30
Sex Age groups Socioeconomic status Comorbidity
Q10%a (N) Male: 8.03 (1,686) 18–35 years: 6.62 (1,247) Low: 8.23 (720) None: 7.33 (2,573)
Female: 7.41 (2,168) 36–65 years: 8.10 (1,880) Middle: 7.4 (2,844) Any: 8.77 (1,033)
> 66 years: 8.7 (652) High: 8.17 (327)
Country BE DK FR GER HU IT NL NO PL RUS ES TR UK
Q10%a (n) 4.2 (250) 6.8 (265) 2.1 (126) 7.2 (290) 6.7 (261) 9.6 (527) 5.6 (235) 9.8 (534) 8.4 (275) 9 (273) 7.4 (274) 4 (270) 6.5 (213)
aThe percentage of the mean score of Question10 (therapy issues) relative to the mean total DLQI score. bDifferent values due to more missing numbers when regression 
analysis is performed. cIncluding nail diseases, hyperhidrosis and granuloma annulare. dIncluding pyoderma gangrenosum, Behçet’s syndrome, panniculitis, necrobiosis 
lipoidica. eEffluvium, androgenic alopecia, cicatricial alopecia, other hair/scalp conditions. fOther than psoriasis: parapsoriasis, pityriasis rubra pilaris, pityriasis lichenoides, 
pityriasis rosea, Darier’s disease. gStomatitis, glossitis, cheilitis, aphthae. hLichen sclerosus, pruritus/eczema vulvae, scroti et ani, balanitis/balanoposthitis. iSkin check 
of organ transplant recipients, other follow-up or uncertain diagnosis.
SD: standard deviation; BE: Belgium; DK: Denmark FR: France; GER: Germany; HU: Hungary; IT: Italy; NL: The Netherlands; NO: Norway; PL: Poland; RUS: Russia; 
ES: Spain; TR: Turkey; UK: United Kingdom.
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that addresses therapy burden (Table III), although the 
DLQI is the most widely used measure in dermatology 
(14) the issue of therapy is little explored.
There are very few studies evaluating the contribution 
of therapy to impairment of HRQoL. In 3 studies (15–17) 
the generic instrument Short Form Health Survey (SF-36) 
was used in random samples of the population. A large 
proportion of patients reported dermatological problems 
and those using topical therapies on prescription showed 
greater impairment of HRQoL than those not using topi-
cal prescription medicines (15). An overview of the most 
relevant results for several diagnoses is given below.
Blistering diseases showed the highest impairment 
due to therapy and positive standardized β values as high 
as 0.5, in support of the high impairment caused by the 
disease and its therapy and not because of the age, sex, 
comorbidity or socioeconomic status of the patients.
HS results in severely impaired HRQoL (18, 19), has 
the highest mean DLQI, but scores for Q10% are low. 
Studies of the same data-set rank HS patients with some 
of the lowest HRQoL (8), highest risk for psychiatric 
comorbidity (7, 20) and impairment in sexual life (9). 
Despite very high impairment of HRQoL, therapy con-
tributes little to this burden.
AD and psoriasis rank highly when mean DLQI, po-
sitive answers to therapy issues or Q10% are evaluated, 
suggesting that these patients are equally adversely af-
fected by all aspects of HRQoL, including therapy.
Diseases affecting small areas of the body, such as 
facial dermatoses (seborrhoeic dermatitis, rosacea and 
acne), as well as psychodermatological conditions rank 
lower on therapy relative to the total DLQI than might 
be expected, demonstrating that it is the disease itself 
and not the therapy that is the driving cause of HRQoL 
impairment. Treating these conditions adequately should 
alleviate the patient’s experienced burden without ad-
ditional impairment.
In contrast, patients with AK, NMSC, allergic/drug 
reactions, scars/fibrosis and morphea, who do not report 
severe impairment of HRQoL as measured by the mean 
DLQI, rank highly in impairment when assessing therapy 
as a percentage of this total score. AK and NMSC do not 
apparently have a high impact on HRQoL, nor psychiatric 
comorbidity (7, 8, 20), but score relatively worse when 
therapy is assessed, ranking them higher than HS and 
several other diseases. 
Studies evaluating the burden caused by AK and/
or NMSC have shown low impact on HRQoL of these 
diseases (21–24), raising the possibility that currently av-
ailable measures may be missing therapy issues and that 
there may be a need for a skin-cancer-specific HRQoL 
measure. Existing disease-specific instruments do not 
include therapy questions (22, 25) (Table III).
Burdensome treatments have a negative effect on adhe-
rence to therapy (5) and can be the reason for undertreat-
ment and relapse of disease. Measuring HRQoL without 
taking into account therapy issues may not represent 
the true extent of suffering that dermatological patients 
experience. On the other hand, knowing which diseases 
have the highest potential to cause therapy issues can alert 
clinicians to which patients need a different approach, 
by giving them better information, providing a variety 
of options, offering training in therapy application, or at 
least acknowledging the issue.
When developing clinical guidelines in dermatology, 
optimization of therapy and minimizing the burden of 
treatment should be considered. Developers of HRQoL 
instruments should pay attention to therapy issues when 
measuring HRQoL in some specific diagnoses, such as 
Table III. Overview of dermatology-specific, disease-specific and 
generic instruments assessing quality of life with comments on 
whether the impact of therapy is addressed in the questionnaire
Type and name of instrument
Therapy 
impact Authors, year
Dermatology-specific instruments
DLQI Yes Finlay & Khan 1994 (6)
Skindex, Skindex-29, 
Skindex-16, Skindex-17
No Chren et al. 1996 (28), Nijsten et 
al. 2006 (29) 
DSQL No Anderson & Rajagopalan 1997 (30)
DQOLS No Morgan et al. 1997 (31)
Disease-specific instruments
PDI Yes Finlay & Kelly 1987 (32)
PSORIQoL Yes McKenna et al. 2003 (33)
RosaQuol Yes Nicholson et al. 2007 (34)
QOLHEQ Yes Ofenloch et al. 2014 (35)
VEINES-QOL Yes Bland et al. 2015 (36)
CADI No Motley & Finlay 1992 (37)
DSQL – Contact dermatitis No Anderson & Rajagopalan 1997 (30)
DSQL – Acne version No Anderson & Rajagopalan 1997 (30)
WAA Questionnaire No Dolte et al. 2000 (38)
Acne-QoL Questionnaire No Martin et al. 2001 (39)
PSS-AD in adults No Ando et al. 2006 (40)
SCI No Rhee et al. 2006 (41)
AAQ No Endo et al. 2012 (42)
MELASQoL Scale No Lieu & Pandaya 2012 (43)
AKQoL questionnaire No Esman et al. 2013 (25)
AA-QLI No Fabbrocini et al. 2013 (44)
FQL index No Heisterberg et al. 2013 (45)
VitiQoL No Lilly et al. 2013 (46)
ABQOL No Sebaratnam et al. 2013 (47)
Generic instruments*
TSQM Yes Atkinson et al. 2004 (4)
SATMED-Q Yes Ruiz et al. 2008 (3)
EuroQol (EQ5D) No EuroQolGroup 1990 (48)
Medical Outcome Study (MOS)
MOS Short-Form 36 (SF-36)
No
No
Ware & Sherbourne 1992 (49)
WHOQoL-100 
WHOQoL-BREF
No
No
WHO 1996 (50)
WHO 1998 (51)
*Only the most commonly used generic instruments that do not address therapeutic 
issues are shown here.
DLQI: Dermatology Life Quality Index; DSQL: Dermatology-Specific Quality of 
Life; DQOLS: Dermatology Quality of Life Scales; PDI: Psoriasis Disability 
Index; PSORIQoL: Psoriasis Index of Quality of Life; RosaQuol: Rosacea Quality 
of Life; QOLHEQ: Quality of Life Hand Eczema Questionnaire; VEINES-QOL: 
Venous Insufficiency Epidemiological and Economic Study; CADI: Cardiff Acne 
Disability Index; WAA: Women with Androgenetic Alopecia; Acne-QoL: Acne-
specific Quality of Life; PSS-AD: Psychosomatic Scale for Atopic Dermatitis; 
SCI: Skin Cancer Index; AAQ: Alopecia Areata Quality of Life; MELASQoL: 
Melasma Quality of Life; AKQoL: Actinic Keratosis Quality of Life; AA-QLI: 
Alopecia Areata Quality of Life Index; FQL index: Fragrance Allergy QoL instrument; 
VitiQoL: Vitiligo Quality of Life Index; ABQOL: Autoimmune Bullous Disease QoL 
Questionnaire; TSQM: Treatment Satisfaction Questionnaire for Medication; 
SATMED-Q: Satisfaction with Medicines Questionnaire.
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skin cancer, as this burden may go undetected using cur-
rently available measures (7, 8, 20–23).
Strengths and limitations
The high number of patients in this study, the unbiased 
selection of participants and adjusting for confounding 
factors resulted in robust data on therapy as a factor 
contributing to impairment in HRQoL. Similar studies 
on therapeutic issues are lacking and studies using DLQI 
typically have no healthy control group.
One potential limitation is in the detail of the wording 
of DLQI question 10: “(…by making your home messy, 
or by taking up time)”, which may bias the respondents 
into only considering topical therapy. However, the main 
question itself is neutral on this point “…how much of a 
problem has the treatment for your skin been…”.
Detailed information on all treatments used by our 
patients was not obtained systematically. The presented 
data evaluate therapy issues on a general basis. Further 
studies evaluating specific dermatological treatments 
are warranted.
Although we refer to data from each country, the data 
was based on 1 centre from each country (apart from Italy 
and Norway). The recruitment centres may not have been 
representative of clinical practice across each country. 
There were large differences between countries in scores 
assessing impairment, which cannot be readily explai-
ned. The cross-cultural issue is one that is of relevance 
to all HRQoL measures (26). The same limitation may 
apply when comparing diseases (27). The cultural and 
language factors leading to these differences are not fully 
understood, though they should be taken into account 
when making any cross-cultural comparisons and when 
using HRQoL data as a guide to optimal health policies 
and creating optimal treatment guidelines. Analysis of 
the source for country differences may be able to serve 
as a guide to optimal health policies and creating optimal 
treatment guidelines.
Conclusion
Treatments for skin diseases contribute to the burden on 
HRQoL. For some diagnoses, therapy may have a larger 
impact than was previously known, but we also identify 
diseases that are affected by therapy to a lesser degree. 
Older, male patients with lower socioeconomic status 
and comorbidities experience more adverse issues with 
therapy. This study highlights new aspects to HRQoL 
that may have previously been overlooked. Clinicians 
are made aware of the importance in addressing therapy 
issues and promoting adherence to therapy, and pharma-
ceutical companies of the ease of use of their products. 
Developers of HRQoL instruments should consider 
including therapy-related questions. The ultimate goal 
would be to reduce the burden of skin disease and pro-
mote adherence to therapy.
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